GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Orthofix Medical Inc (NAS:OFIX) » Definitions » ROE %
中文

Orthofix Medical (Orthofix Medical) ROE % : -14.61% (As of Dec. 2023)


View and export this data going back to 1992. Start your Free Trial

What is Orthofix Medical ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Orthofix Medical's annualized net income for the quarter that ended in Dec. 2023 was $-88.7 Mil. Orthofix Medical's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $607.1 Mil. Therefore, Orthofix Medical's annualized ROE % for the quarter that ended in Dec. 2023 was -14.61%.

The historical rank and industry rank for Orthofix Medical's ROE % or its related term are showing as below:

OFIX' s ROE % Range Over the Past 10 Years
Min: -32.36   Med: -1.91   Max: 4.37
Current: -26.51

During the past 13 years, Orthofix Medical's highest ROE % was 4.37%. The lowest was -32.36%. And the median was -1.91%.

OFIX's ROE % is ranked worse than
68.31% of 811 companies
in the Medical Devices & Instruments industry
Industry Median: 0.29 vs OFIX: -26.51

Orthofix Medical ROE % Historical Data

The historical data trend for Orthofix Medical's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orthofix Medical ROE % Chart

Orthofix Medical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8.59 0.74 -11.06 -5.86 -32.36

Orthofix Medical Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.43 -48.70 -24.19 -18.39 -14.61

Competitive Comparison of Orthofix Medical's ROE %

For the Medical Devices subindustry, Orthofix Medical's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orthofix Medical's ROE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Orthofix Medical's ROE % distribution charts can be found below:

* The bar in red indicates where Orthofix Medical's ROE % falls into.



Orthofix Medical ROE % Calculation

Orthofix Medical's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-151.395/( (336.86+598.73)/ 2 )
=-151.395/467.795
=-32.36 %

Orthofix Medical's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-88.696/( (615.483+598.73)/ 2 )
=-88.696/607.1065
=-14.61 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Orthofix Medical  (NAS:OFIX) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-88.696/607.1065
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-88.696 / 801.66)*(801.66 / 915.4835)*(915.4835 / 607.1065)
=Net Margin %*Asset Turnover*Equity Multiplier
=-11.06 %*0.8757*1.5079
=ROA %*Equity Multiplier
=-9.69 %*1.5079
=-14.61 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-88.696/607.1065
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-88.696 / -88.196) * (-88.196 / -58.38) * (-58.38 / 801.66) * (801.66 / 915.4835) * (915.4835 / 607.1065)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.0057 * 1.5107 * -7.28 % * 0.8757 * 1.5079
=-14.61 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Orthofix Medical ROE % Related Terms

Thank you for viewing the detailed overview of Orthofix Medical's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Orthofix Medical (Orthofix Medical) Business Description

Traded in Other Exchanges
Address
3451 Plano Parkway, Lewisville, TX, USA, 75056
Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two main segments: global spine, including bone growth and healing therapies, spinal implants, and regenerative tissue products; and global orthopedics, providing products used in fracture repair, deformity correction, and bone reconstruction procedures. The majority of the company's sales come from the global spine segment in the United States. Orthofix distributes its products throughout North America, Europe, and several countries globally. The company provides solutions to hospitals, physicians, other healthcare providers, and patients.
Executives
James F. Hinrichs director 3750 TORREY VIEW COURT, SAN DIEGO CA 92130
Puja Leekha officer: CECO & Interim CLO 3451 PLANO PARKWAY, LEWISVILLE TX 75056
Geoffrey C Gillespie officer: VP, Controller, Interim CFO 3451 PLANO PARKWAY, LEWISVILLE TX 75056
Kevin J. Kenny officer: President of Global Spine C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Shweta Maniar director C/O SEASPINE HOLDINGS CORP, 5770 ARMADA DRIVE, CARLSBAD CA 92008
Stuart Essig director 311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536
John J. Bostjancic officer: CFO C/O SEASPINE HOLDINGS CORPORATION, 2302 LA MIRADA DRIVE, VISTA CA 92081
Keith Valentine director, officer: President & CEO 7475 LUSK BLVD., SAN DIEGO CA 92121
Henneman John B Iii director 311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Patrick L Keran officer: Chief Legal Officer 6725 MESA RIDGE RD., SUITE 100, SAN DIEGO CA 92121
Thomas A. West director C/O INTERSECT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Michael E Paolucci director 7475 LUSK BLVD., SAN DIEGO CA 92121
Catherine M Burzik director
Rice Doug officer: CFO 3451 PLANO PARKWAY, LEWISVILLE TX 75056
Kimberley A. Elting officer: Chief Legal Officer 3451 PLANO PARKWAY, LEWISVILLE TX 75056

Orthofix Medical (Orthofix Medical) Headlines

From GuruFocus